BS

Bristol-Myers Squibb

Every trial this sponsor leads in the registry, and everything it has published.

1,867All trials
Recruiting115
Recruited91
Not yet recruiting20
Completed1,348
Stopped285
Other8

226 active · 12% of this sponsor’s registry footprint

Oncology122 trials
Neurology18 trials
Psychiatry & Addiction17 trials
Immunology & Inflammation16 trials
Cardiovascular14 trials
Dermatology13 trials
Haematology5 trials
Respiratory4 trials

Not shown above: 12 Phase 1 healthy-volunteer trials and 2 trials whose condition matched no therapy area.

Trials by phase

Phase 1860
Phase 2451
Phase 3363
Phase 459
Unphased134

Pipeline by phase · 64 drugs in active development

Phase 3 · 18 drugs

Nivolumab11 trials · 2 recruitingest. Sept 2026
Adagrasib (MRTX849)8 trials · 4 recruitingest. Oct 2026
Pumitamig7 trials · 7 recruitingest. Sept 2028
Golcadomide (BMS-986369, CC-99282)6 trials · 1 recruitingest. Dec 2026
Iza-Bren (BMS-986507)5 trials · 4 recruitingest. Mar 2028
Repotrectinib5 trials · 3 recruitingest. Sept 2026
Zolacabtagene Autoleucel (BMS-986353, CC-97540)5 trialsest. Jul 2027
Mezigdomide (CC-92480)4 trials · 2 recruitingest. Oct 2026

Phase 2 · 10 drugs

Navlimetostat (BMS-986504, MRTX1719)10 trials · 7 recruitingest. Dec 2026
Delocamten (BMS-986435)3 trials · 2 recruitingest. Dec 2026
Irafamdastat (BMS-986368)3 trials · 2 recruitingest. Feb 2027
Oral Azacitidine (CC-486)3 trialsest. Jul 2028
BMS-9864462 trialsest. Mar 2027
Fludarabine2 trials · 1 recruitingest. Mar 2029
Gene-modified (GM) T cell therapy1 trial · 1 recruitingest. Nov 2036

Phase 1 · 30 drugs

Avadomide (CC-122)1 trialest. Oct 2026
BMS-9855211 trial · 1 recruitingest. Nov 2026
BMS-9864491 trialest. Sept 2026
BMS-9864531 trial · 1 recruitingest. May 2030
BMS-9864541 trial · 1 recruitingest. Jun 2027
BMS-9864631 trial · 1 recruitingest. Dec 2028
BMS-9864701 trial · 1 recruitingest. Jan 2027
BMS-9864821 trial · 1 recruitingest. Jan 2029

Phase 4 · 6 drugs

Xanomeline/Trospium Chloride27 trials · 23 recruitingest. Oct 2026
Deucravacitinib (BMS-986165)22 trials · 11 recruitingest. Oct 2026
Mavacamten12 trials · 8 recruitingest. Nov 2026
Luspatercept (ACE-536)10 trials · 2 recruitingest. Jul 2027
Ozanimod (BMS-986374)4 trials · 3 recruitingest. Dec 2028
Nivolumab/Relatlimab3 trialsest. May 2029

Not counted above: 1 combination backbone (established drugs used alongside the assets) and 7 unphased interventions.

Active trials only, code names and brands merged. 1,348 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 5 of 10 curated

Non-small cell lung cancer (Oncology)27 trials · 11 recruiting · 13 drugs1.9% of landscape
Multiple myeloma (Oncology)14 trials · 7 recruiting · 8 drugs1.8% of landscape
Breast cancer (Oncology)7 trials · 4 recruiting · 5 drugs0.2% of landscape
Alzheimer's disease (Neurology)6 trials · 5 recruiting · 3 drugs1.6% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)1 trial · 1 recruiting · 1 drug0.6% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon